United Maritime Capital’s AstraZeneca AZN Stock Holding History

United Maritime Capital’s Portfolio AZN Stock Details AZN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q1	–	Sell	-475	Closed	-$47K	–	80
2020 Q4	$47K	Buy	+475	New	+$50.3K	0.04%	79

Other funds holding AZN

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

Fisher Asset Management Camas, Washington $336B AUM 34.66% 1-Year Est. Return

GQG Partners Ft. Lauderdale, Florida $53.8B AUM 19.23% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return

United Maritime Capital's AZN Position: Q1 2021 in Review

United Maritime Capital sold out of AstraZeneca (AZN) in Q1 2021, closing a stake of 475 shares — an estimated $47K sold.

United Maritime Capital first reported a position in AZN in Q4 2020 and held it in 1 quarter. The position peaked at $47K in Q4 2020. 756 funds tracked by Wall St. Rank hold AZN as of Q1 2021.

United Maritime Capital reported no remaining AstraZeneca position as of Q1 2021 after selling out during the quarter.
United Maritime Capital sold 475 AstraZeneca shares in Q1 2021, an estimated $47K.
United Maritime Capital first reported a position in AstraZeneca in Q4 2020 and held it in 1 quarter.
United Maritime Capital's AstraZeneca position peaked at $47K in Q4 2020.
756 funds tracked by Wall St. Rank held AstraZeneca as of Q1 2021.

Based on United Maritime Capital's 13F filing for Q1 2021, filed 7 May 2021.